CENTOGENE’s NGS disease panels are at the forefront of medical advances, offering patients and their families rapid, comprehensive and affordable diagnostic solutions.
We were born to help diagnosing patients with rare disease and today we evolved to help patients of all clinical specialities. We have now carefully curated our NGS panels to reflect our growing knowledge of complex gene-disease associations, drawing on 20 years of diagnostic experience and clinical genetic expertise in solving patients’ diagnostic odysseys.
NOW, with the Power of CentoGenome!
Using the genome as the backbone for neurology panels increases the diagnostic yield by enabling screening of known repeat expansions associated with neurological disorders and complex-to-sequence variants in GBA1 and SMN1. It also enables interrogation of non-coding genes with an established association with neurology.
CentoNeuro Upgraded is our largest neurology panel, designed to detect a wide range of neurological disorders. This panel is intended for patients with clinical features suggestive of epilepsies, dementia, movement disorders, and spasticity, including ataxia disorders and Parkinson’s disease; neuromuscular disorders; cerebrovascular disorders; hyperekplexia; paroxysmal disorders; and neurostructural disorders, among others. Please note that repeat expansion disorders, SMN1 CNV analysis, and GBA conversion analysis with its pseudo gene are not covered by this panel. If there is clinical suspicion of these conditions, the Genome version of this panel is recommended.
Learn more| TAT | 25 business days |
| Methods | NGS including CNV analysis |
CentoNeuro Upgraded Genome is our largest neurology panel, designed to detect a wide range of neurological disorders. This panel is intended for patients with clinical features suggestive of epilepsies, dementia, movement disorders, and spasticity, including ataxia disorders and Parkinson’s disease; neuromuscular disorders; cerebrovascular disorders; hyperekplexia; paroxysmal disorders; and neurostructural disorders, among others. This version of the panel is based on genome sequencing and includes the non-coding genes RNU4-2, RNU7-1, and SNORD118; repeat expansion screening of AR, ATN1, ATXN1, ATXN10, ATXN2, ATXN3, ATXN7, ATXN8OS, C9orf72, CACNA1A, CNBP, CSTB, DMPK, FMR1, FXN, HTT, JPH3, NOP56, PABPN1, PHOX2B, PPP2R2B, PRNP, and TBP; GBA1 conversion analysis with its pseudogene; and SMN1 CNV analysis.
Learn more| TAT | 25 business days |
| Methods | NGS including CNV analysis |
Whole Genome Sequencing (WGS), offers the most comprehensive one-step solution with the highest diagnostic yield
Whole Exome Sequencing (WES) enables quicker and cost-effective diagnosis for patients with complex and unclear symptoms
Multiomics give a deeper understanding of human biological processes and acts as a unique and highly effective tool for early diagnosis
Create a diagnostic gene panel by selecting genes tailored to individual patient needs.
2 to >4.000
Selectable Genes
15 Business Days
TAT
Genome or Exome
Backbone
Our global network of customer support and experts guiding you every step of the way.
Send us a messageRegional Support
